by Raynovich Rod | Nov 29, 2012 | BIOgraph, Biopharmaceuticals
Rayno Life Science Stocks Move Higher Biotech stocks are ignoring the volatility from the political fray today with big moves in many Rayno Life Science stocks and a 1.5% move in the bellwether ETF (IBB).The tech heavy QQQ lagged up only 0.7%. Overall, despite the...
by Raynovich Rod | Nov 20, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany...
by Raynovich Rod | Nov 16, 2012 | BIOgraph, Macro
Politicians Offer Hope Of Deal and Are Looking For Common Ground Boehner puts revenue on the table passing off next move to DEMS for cuts. Reid says he will not wait till end of the year to cut a deal. S&P goes from down 10 to up 4. NASDAQ up 7. AAPL rallies from...
by Raynovich Rod | Nov 15, 2012 | BIOgraph, Clinical Diagnostics and Tools
Response Genetics (RGDX) Offers Good Value and Is Positioned For Revenue Growth In April we compared two emerging companies focused in biomarker diagnostics, BG Medicine, Inc. and Vermillion, Inc. offering a challenge to readers as to which stock would be the winner...
by Raynovich Rod | Nov 12, 2012 | BIOgraph, Biopharmaceuticals
A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on...
by Raynovich Rod | Nov 9, 2012 | BIOgraph, Biopharmaceuticals
Trends from early trading show promise for intermediate support in larger cap biotech shares today with the NASDAQ up 0.5% in early trading. This could be a good day for covering shorts and re-balancing in anticipation for a Q4 rally : The IBB (130.82) is up 1.88%....
by Raynovich Rod | Nov 7, 2012 | BIOgraph, Macro
Draghi Comments Trigger Sell-Off of 2% with Bottom Holding-Euro Down, Bonds Up Mario Draghi sparked the current 2012 rally in July saying he would support the Euro no matter what. Today reality set in as a weak German economy and riots in Greece remind us that little...
by Raynovich Rod | Nov 1, 2012 | BIOgraph, Clinical Diagnostics and Tools
CSII ($12.17) stock is up 4.2% on sales growth in treatment of Peripheral Artery Disease (PAD) Cardiovascular Systems revenues were up 25% over Fiscal Q1 2012 to $23.3M . The Q1 2013 loss was $5,2M or 26 cents a share. Shareholder equity is $28.9M with $32M in cash...
by Raynovich Rod | Oct 31, 2012 | BIOgraph, Biopharmaceuticals
Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with...
by Raynovich Rod | Oct 23, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph, Clinical Diagnostics and Tools
Cepheid in Low $30’s- Long Term Buy Cepheid is not a cheap stock with a Price to Sales of 6.82, market cap of $2.10B and a forward PE of 122.58 but we see a capitulation of sellers who were playing the MO game with a very expensive stock. Nonetheless Cepheid is...
